James Edgemond Sells 10,000 Shares of United Therapeutics (NASDAQ:UTHR) Stock
by Doug Wharley · The Cerbat GemUnited Therapeutics Corporation (NASDAQ:UTHR – Get Free Report) CFO James Edgemond sold 10,000 shares of the stock in a transaction dated Monday, April 6th. The stock was sold at an average price of $558.40, for a total value of $5,584,000.00. Following the transaction, the chief financial officer directly owned 18,876 shares in the company, valued at approximately $10,540,358.40. The trade was a 34.63% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
James Edgemond also recently made the following trade(s):
- On Thursday, April 2nd, James Edgemond sold 10,000 shares of United Therapeutics stock. The shares were sold at an average price of $561.50, for a total value of $5,615,000.00.
- On Monday, March 30th, James Edgemond sold 10,000 shares of United Therapeutics stock. The shares were sold at an average price of $593.17, for a total value of $5,931,700.00.
- On Thursday, March 26th, James Edgemond sold 10,000 shares of United Therapeutics stock. The shares were sold at an average price of $535.90, for a total value of $5,359,000.00.
- On Monday, March 23rd, James Edgemond sold 10,000 shares of United Therapeutics stock. The shares were sold at an average price of $527.48, for a total value of $5,274,800.00.
United Therapeutics Stock Performance
UTHR stock traded up $6.05 during mid-day trading on Tuesday, reaching $565.70. The company had a trading volume of 726,424 shares, compared to its average volume of 499,973. United Therapeutics Corporation has a fifty-two week low of $266.98 and a fifty-two week high of $607.89. The company has a market capitalization of $24.79 billion, a price-to-earnings ratio of 20.28, a price-to-earnings-growth ratio of 1.63 and a beta of 0.75. The firm has a fifty day simple moving average of $508.43 and a 200 day simple moving average of $480.83.
United Therapeutics (NASDAQ:UTHR – Get Free Report) last issued its earnings results on Wednesday, February 25th. The biotechnology company reported $7.70 earnings per share for the quarter, topping the consensus estimate of $6.78 by $0.92. United Therapeutics had a return on equity of 19.30% and a net margin of 41.94%.The business had revenue of $790.20 million for the quarter, compared to analyst estimates of $814.80 million. During the same quarter last year, the company earned $6.19 EPS. The business’s quarterly revenue was up 7.4% on a year-over-year basis. As a group, analysts predict that United Therapeutics Corporation will post 24.48 earnings per share for the current year.
Analysts Set New Price Targets
Several brokerages have recently weighed in on UTHR. Wells Fargo & Company raised their target price on United Therapeutics from $486.00 to $575.00 and gave the stock an “equal weight” rating in a research report on Tuesday, March 31st. Cantor Fitzgerald lifted their price target on United Therapeutics from $525.00 to $625.00 and gave the stock an “overweight” rating in a research report on Thursday, March 12th. HC Wainwright lifted their price target on United Therapeutics from $600.00 to $660.00 and gave the stock a “buy” rating in a research report on Tuesday, March 31st. Oppenheimer lifted their price target on United Therapeutics from $575.00 to $600.00 and gave the stock an “outperform” rating in a research report on Thursday, February 26th. Finally, Weiss Ratings reaffirmed a “buy (b)” rating on shares of United Therapeutics in a research report on Monday, December 29th. Nine research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $586.00.
Get Our Latest Research Report on UTHR
Institutional Inflows and Outflows
Several hedge funds and other institutional investors have recently modified their holdings of UTHR. Geneos Wealth Management Inc. boosted its stake in shares of United Therapeutics by 141.7% in the first quarter. Geneos Wealth Management Inc. now owns 145 shares of the biotechnology company’s stock valued at $45,000 after buying an additional 85 shares in the last quarter. Northwestern Mutual Wealth Management Co. raised its holdings in United Therapeutics by 18.8% during the second quarter. Northwestern Mutual Wealth Management Co. now owns 443 shares of the biotechnology company’s stock worth $127,000 after purchasing an additional 70 shares during the last quarter. Quantbot Technologies LP raised its holdings in United Therapeutics by 25.2% during the second quarter. Quantbot Technologies LP now owns 2,331 shares of the biotechnology company’s stock worth $670,000 after purchasing an additional 469 shares during the last quarter. EverSource Wealth Advisors LLC raised its holdings in United Therapeutics by 271.9% during the second quarter. EverSource Wealth Advisors LLC now owns 740 shares of the biotechnology company’s stock worth $213,000 after purchasing an additional 541 shares during the last quarter. Finally, Amundi raised its holdings in United Therapeutics by 3.6% during the second quarter. Amundi now owns 362,826 shares of the biotechnology company’s stock worth $107,113,000 after purchasing an additional 12,633 shares during the last quarter. 94.08% of the stock is currently owned by hedge funds and other institutional investors.
United Therapeutics Company Profile
United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.